CURRICULUM VITAE KIRK GEORGE VOELKER, M.D.

Transcription

1 PERSONAL INFORMATION DATE OF BIRTH December 29, 1961 PLACE OF BIRTH OFFICE ADDRESS Buffalo, NY State St (941)

2 ACADEMIC RECORD UNDERGRADUATE MEDICAL SCHOOL INTERNSHIP RESIDENCY CHIEF RESIDENT FELLOWSHIP University of FL. Gainesville, FL. August, 1980-May, 1985 Degree-Bachelor of Science, Engineering Biomedical Engineering) University of FL. Gainesville, FL. August, 1985-May, 1989 Degree-Doctor of Medicine Orlando Regional Medical Center 1414 S. Kuhl Ave. Orlando, FL. July, 1989-June, 1990 Orlando Regional Medical Center 1414 S. Kuhl Ave. Orlando, FL. July, 1990-June, 1992 Orlando Regional Medical Center 1414 S. Kuhl Ave. Orlando, FL. July, 1991-June, 1992 Pulmonary & Critical Care Medicine University of CA. at Irvine Long Beach, VA. July, 1992-June, 1995 Suncoast Lung Ctr. November, 1995-July, 1997 Solo Practice July, 1997-August, 1997 Lung Associates Partner- August, June 2005 of Sarasota

3 Solo Practice AMI Stop Smoking Clinics Quit Doc Smoking Treatment Network June Present Founder - January Present Co-Founder June Present HOSPITAL AFFILIATIONS Sarasota Memorial Hospital 12/95-Present Doctors Hospital of Sarasota 11/ HEALTHSOUTH Rehabilitation Hospital 05/97-Present LICENSURE BOARD CERTIFICATION MEMBERSHIP FL ME58833 CA GO73832 American Board of Internal Medicine Internal Medicine 1992 Pulmonary Medicine 11/94 Critical Care Medicine 11/95 American College of Chest Physicians American College of Physicians American Medical Association American Thoracic Society (UCI Fellowship Representative `92-`94) Florida Medical Association (Regional Representative `90-`92) Orange County Medical Society (Resident Representative `90-`92) Society of Critical Care Medicine Sarasota County Medical Society PUBLICATIONS Co-Author

4 Current Clinical Strategies in Critical Care Medicine (second ed.) 1993: Clinical Strategies Publishing: Fountain Valley, CA. Co-Author Current Clinical Strategies in Critical Care Medicine (third ed.) 1995: PUBLICATIONS(Cont) Pulm. Vascular and Thromboembolic Dis. Chapter in: Handbook of Pulmonary and Critical Care Medicine Brenner M, Williams J. Diagnostic and Treatment Strategies in Massive Hemoptysis Chapter in: Handbook of Pulmonary and Critical Care Medicine Brenner M, Williams J. Sasse S, Voelker K, Mahutte CK Arterial Oxygenation Time after an Increase in the Concentration of Inspired Oxygen in Mechanically Ventilated Medical ICU Pts. American Journal of Respiratory and Critical Care Voelker K, Chetty C, Sasse S,Mahutte CK Tracheomalacia Presenting as COPD. CHEST Voelker K, Chetty C, Mahutte CK RhDNAse in the Treatment of Atelectasis in Spinal Cord Patients Critical Care Medicine Improved Diagnostic Sensitivity for Lung Cancer Using an Automated Quantitative Cytology System and Uridine 5'-Triphosphate-Induced Sputum Specimens. Chest, May 2004; 125: 157S - 158S

5 Efficacy Of A County Government Employee Benefits Smoking Cessation Program Utilizing An Anticholinergic Intramuscular Injection Combined With Counseling Chest Meeting Abstracts, Oct 2005; 128: 387s. PUBLICATIONS(Cont) PROCEDURES RESEARCH Safety And Efficacy Of An Anticholinergic Injection Used In A Community Smoking Cessation Clinic Chest Meeting Abstracts, Oct 2004; 126: 713s. All aspects of pulmonary and critical care medicine, including training in: -Hyperbaric Oxygen Therapy -Rigid Bronchoscopy -Laser Bronchoscopy -Percutaneous Tracheostomy -Stent Placement -Thoracoscopy -Ultrasonic Bronchoscopy -Argon Plasma Coagulation Bronchoscopy -Photodynamic Therapy Bronchoscopy -Endobronchial Volume Reduction Surgery Clinical Research Center 1425 S. Osprey Ave., Suite CLINICAL TRIALS CONDUCTED IN CONJUNCTION WITH CLINICAL RESEARCH CENTER OF SARASOTA MEMORIAL HOSPITAL: Hospital). Bayer Drug Study #98-PULM-45. Prospective, randomized, double-blind, multicenter comparison of the safety

6 and efficacy of Moxifloxacin 400 mg QD for five days versus Azithromycin 250 mg QD (500 mg QD on the first day) for five days in the treatment of acute exacerbation of chronic bronchitis. Protocol # (December, 1997-February, 1999) Sub-Investigator Clinical Research Center of Sarasota Memorial Hospital). Bayer Drug Study #99-PULM-55. Prospective, randomized, double-blind, multicenter comparison of the safety and efficacy of Moxifloxacin 400 mg QD for five days versus Levofloxacin 500 mg QD for seven days in the treatment of acute exacerbation of chronic bronchitis. Protocol # (October, 1999-May, 2000) Hospital). Bayer #00-PULM-39. Prospective, randomized, doubleblind study comparing Faropenem Daloxate 300 mg PO BID for 5 days with Azithromycin for 5 days (500 mg PO day 1, then 250 mg PO OD days 2-5) in the treatment of patients with acute exacerbation of chronic bronchitis. Protocol # (December, ) Hospital). #99-PULM-47. A Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-ranging evaluation of the safety and efficacy of a-hanp infusion (Carperitide for injection: SUN 4936) in patients with acute respiratory distress syndrome (ARDS). Protocol #SPI-001 (July, ) Hospital). A one-year randomized, double-blind, placebo and active-controlled parallel design safety and efficacy comparison of COMBIVENT HFA Inhalation Aerosol to COMBIVENT CFC Inhalation Aerosol in patients with COPD. (November, ) Hospital). #00-MEDI-21. A randomized, open-label, pilot assessment of the effect of Protonix Iv for injection (Pantoprazole Sodium) on gastric Ph in ICU patients. (August, )

7 Hospital). A randomized, multicenter, open-label trial comparing intravenous Zithromax (Azithromycin) plus intravenous Rocephin (Ceftriaxone) followed by oral Zithromax (Azithromycin) with intravenous Levaquin (Levofloxacin) followed by oral Levaquin (Levofloxacin) for the treatment of moderate to severely ill subjects with community-acquired pneumonia. Protocol #A (December, ) Hospital). A randomized, double-blind, multicenter study to evaluate the effect of adding either Montelukast Sodium or Salmeterol Xinafoate to inhaled Fluticasone in adult asthmatics. (February, 2000-December, 2000) Hospital) A one-year randomized, double-blind, placebo and active controlled parallel design safety and efficacy comparison of COMBIVENT HFA Inhalation Aerosol to COMBIVENT (CFC) Inhalation Aerosol in patients with COPD Hospital) A Prospective, randomized, double-blind, multicenter outpatient trial comparing the safety and efficacy of moxifloxacin 400 mg PO QD for 5 days vs. azithromycin 500 mg PO loading dose on day 1, then 250 mg PO QD for 4 days for the treatment of Acute Exacerbations of Chronic Bronchitis ( The QUICK Study) STUDY NUMBER: Hospital) A Randomized, 24-week, Double-blind, Placebocontrolled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Ariflo (15 mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD) 00-PULM-51 Hospital) Prospective, randomized, double-blind study comparing Faropenem Daloxate 300mg PO BID for 5 days with Azithromycin for 5 days (500mg PO day 1, then 250 mg PO OD days 2-5) in the treatment of patients with acute exacerbation of chronic bronchitis. Bayer Protocol #00-PULM-39.

8 Hospital) A Randomized, Open-Label, Pilot Assessment Of The Effect Of Protonixa Iv For Injection (Pantoprazole Sodium) On Gastric Ph In ICU patients. Hospital) A Multicenter, Randomized, Open-Label Study Comparing The Efficacy And Safety Of Once Daily (O.D.) Org 31540/Sr90107a Versus Adjusted-Dose Intravenous (Iv) Unfractionated Heparin (Ufh) In The Initial Treatment Of Acute Symptomatic Pulmonary Embolism (PE) 01-PULM-03 Hospital) A Double-Blinded, Placebo-Controlled, Parallel Group Study of Uridine 5-Triphosphate (UTP) Solution for Inhalation as an Adjunct in the Diagnosis of Lung Cancer by Sputum Cytology (Inspire Lung CA) 01-PULM-12 Hospital) Title: A randomized, double-blind, placebocontrolled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). SPONSOR: Boehringer Ingelheim Pharmaceuticals, Inc. 02-PULM-21 Hospital) A multicentre, randomized, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol/fluticasone propionate (Seretide /Viani /Advair ) 50/500mg bd, salmeterol 50mg bd and fluticasone propionate 500mg bd, all delivered via the Diskus/ Accuhaler inhaler, on the survival of subjects with chronic obstructive pulmonarydisease (COPD) over 3 years of treatment. 02-PULM-20 Principle-Investigator (Clinical Research Center of Sarasota Memorial Hospital). Endobronchial Valve for Emphysema Palliation Trial (VENT) (February Present